SQI
SciQuest, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Fri, Jul. 1, 10:28 AM
    • GlaxoSmithKline (NYSE:GSK) upgraded to Buy from Neutral by Citigroup. Price target is 1800p (14% upside).
    • Alexion Pharmaceuticals (NASDAQ:ALXN) upgraded to Buy from Neutral by Citigroup. Price target is $154 (29% upside).
    • IPG Photonics (NASDAQ:IPGP) upgraded to Buy from Hold by Canaccord Genuity. Price target raised to $90 (13% upside) from $85.
    • Centene (NYSE:CNC) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $86 (21% upside) from $84.
    • Pacira Pharmaceuticals (NASDAQ:PCRX) downgraded to Hold from Buy by Brean Capital.
    • TESARO (NASDAQ:TSRO) downgraded to Hold from Buy by Jefferies.
    • Esperion Therapeutics (NASDAQ:ESPR) downgraded to Equal Weight from Overweight with a $13 (26% upside) price target (from $28) by Barclays. Downgraded to Neutral from Overweight with a $15 (46% upside) price target (from $50) by JPMorgan. Downgraded to Underperform from Neutral with a $10 (0% upside) price target (from $23) by Credit Suisse.
    • HeartWare International (NASDAQ:HTWR) downgraded to Market Perform from Outperform by Wells Fargo. Downgraded to Neutral from Buy with a $58 (0% upside) price target (from $60) by SunTrust Robinson Humphrey.
    • Regulus Therapeutics (NASDAQ:RGLS) downgraded to Market Perform from Outperform by BMO Capital. Price target lowered to $4 (30% upside) from $16.
    • HealthSouth (NYSE:HLS) downgraded to Underweight from Equal Weight by Barclays. Price target lowered to $42 (8% upside) from $45.
    • SciQuest (NASDAQ:SQI) downgraded to Market Perform from Outperform by Raymond James.
    • Quest Diagnostics (NYSE:DGX) downgraded to from Neutral to Sell by Jyske Bank.
    | Fri, Jul. 1, 10:28 AM | 5 Comments
  • Tue, May 31, 3:00 PM
    | Tue, May 31, 3:00 PM
  • Tue, May 31, 12:50 PM
    | Tue, May 31, 12:50 PM
  • Tue, May 31, 9:15 AM
    | Tue, May 31, 9:15 AM | 2 Comments
  • Tue, May 31, 8:13 AM
    • SciQuest (NASDAQ:SQI) announces it accepted a deal to be acquired by affiliates of PE-firm Accel-KKR for $17.75 per share in a deal valued at $509M. SciQuest closed at $13.27 last Friday.
    • Upon closing, AKKR will own 100% of the outstanding shares of SciQuest . AKKR currently owns 4.9% of SciQuest’s outstanding shares.
    • The transaction is expected to close in Q3 subject to customary closing conditions, including approval of SciQuest’s stockholders and required regulatory approvals. Under the terms of the agreement, SciQuest may solicit alternative acquisition proposals from third parties during a 25-day "go-shop" period, following the date of execution of the merger agreement.
    | Tue, May 31, 8:13 AM | 1 Comment
  • Thu, Apr. 28, 4:31 PM
    • SciQuest (NASDAQ:SQI): Q1 EPS of $0.09 beats by $0.01.
    • Revenue of $26.9M (+3.9% Y/Y) beats by $0.07M.
    | Thu, Apr. 28, 4:31 PM
  • Thu, Feb. 4, 4:10 PM
    • SciQuest (NASDAQ:SQI): Q4 EPS of $0.09 beats by $0.01.
    • Revenue of $26.7M (+4.2% Y/Y) beats by $0.12M.
    | Thu, Feb. 4, 4:10 PM
  • Oct. 29, 2015, 4:44 PM
    • SciQuest (NASDAQ:SQI): Q3 EPS of $0.08 beats by $0.01.
    • Revenue of $26.3M (+1.7% Y/Y) beats by $0.23M.
    | Oct. 29, 2015, 4:44 PM
  • Jul. 30, 2015, 4:20 PM
    • SciQuest (NASDAQ:SQI): Q2 EPS of $0.07 in-line.
    • Revenue of $26.5M (+4.8% Y/Y) beats by $0.03M.
    | Jul. 30, 2015, 4:20 PM
  • Apr. 30, 2015, 4:43 PM
    • SciQuest (NASDAQ:SQI): Q1 EPS of $0.05 in-line.
    • Revenue of $25.97M (-0.7% Y/Y) beats by $0.12M.
    | Apr. 30, 2015, 4:43 PM
  • Feb. 5, 2015, 4:44 PM
    • SciQuest (NASDAQ:SQI): Q4 EPS of $0.07 in-line.
    • Revenue of $25.6M (-4.3% Y/Y) beats by $0.05M.
    | Feb. 5, 2015, 4:44 PM | 1 Comment
  • Oct. 30, 2014, 4:16 PM
    • SciQuest (NASDAQ:SQI): Q3 EPS of $0.07 in-line.
    • Revenue of $25.9M (+10.4% Y/Y) beats by $0.13M.
    | Oct. 30, 2014, 4:16 PM
  • Jul. 30, 2014, 5:31 PM
    • SciQuest (NASDAQ:SQI): Q2 EPS of $0.07 beats by $0.01.
    • Non GAAP Revenue of $25.7M (+16.7% Y/Y) beats by $0.3M.
    | Jul. 30, 2014, 5:31 PM
  • May 2, 2014, 12:49 PM
    | May 2, 2014, 12:49 PM | 2 Comments
  • May 2, 2014, 9:18 AM
    | May 2, 2014, 9:18 AM
  • May 2, 2014, 9:13 AM
    • Revenues: $25.4M (+22.7%).
    • Loss from operations: $0.1M (+92.3%).
    • EPS: breakeven compared to a loss of $0.03 yoy.
    • Q2 guidance:
    • Revenues: $24.8M - $25.2M.
    • EPS: loss of $0.01 - breakeven.
    • 2014 guidance:
    • Revenues: $101.6M - $104.6M.
    • Loss/share: $0.02 - $0.05.
    • CF Ops: $18.4M - $22.4M.
    • (SQI) shares are down 24% premarket on light volume.
    | May 2, 2014, 9:13 AM